

Ling-Pei Ho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1590146/publications.pdf>

Version: 2024-02-01

35
papers

4,457
citations

218592

26
h-index

395590

33
g-index

37
all docs

37
docs citations

37
times ranked

10070
citing authors

#	ARTICLE	IF	CITATIONS
1	An immunodominant NP105â€“113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. <i>Nature Immunology</i> , 2022, 23, 50-61.	7.0	110
2	Namulumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 255-266.	5.2	32
3	Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. <i>Thorax</i> , 2022, 77, 717-720.	2.7	16
4	COVID-19 therapeutics: Challenges and directions for the future. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119893119.	3.3	92
5	Alveolar and lung interstitial macrophages: Definitions, functions, and roles in lung fibrosis. <i>Journal of Leukocyte Biology</i> , 2021, 110, 107-114.	1.5	45
6	BTS Clinical Statement on pulmonary sarcoidosis. <i>Thorax</i> , 2021, 76, 4-20.	2.7	90
7	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 196-206.	5.2	370
8	Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. <i>EClinicalMedicine</i> , 2021, 31, 100683.	3.2	435
9	Multi-Modal Characterization of Monocytes in Idiopathic Pulmonary Fibrosis Reveals a Primed Type I Interferon Immune Phenotype. <i>Frontiers in Immunology</i> , 2021, 12, 623430.	2.2	34
10	P058â€“Persistence of neutrophil abnormalities in COVID-19 convalescence. <i>Rheumatology</i> , 2021, 60, .	0.9	0
11	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	5.8	150
12	Hyperpolarized ¹²⁹ Xe MRI Abnormalities in Dyspneic Patients 3 Months after COVID-19 Pneumonia: Preliminary Results. <i>Radiology</i> , 2021, 301, E353-E360.	3.6	88
13	Symptom Persistence Despite Improvement in Cardiopulmonary Health â€“ Insights from longitudinal CMR, CPET and lung function testing post-COVID-19. <i>EClinicalMedicine</i> , 2021, 41, 101159.	3.2	87
14	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	5.2	394
15	Monocyte and neutrophil levels are potentially linked to progression to IPF for patients with indeterminate UIP CT pattern. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000899.	1.2	15
16	ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 691.	0.7	62
17	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020, 21, 1336-1345.	7.0	1,066
18	Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. <i>Science Immunology</i> , 2020, 5, .	5.6	198

#	ARTICLE	IF	CITATIONS
19	Readily accessible CT scoring method to quantify fibrosis in IPF. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000584.	1.2	11
20	How the Respiratory Epithelium Senses and Reacts to Influenza Virus. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 259-268.	1.4	21
21	The role of respiratory epithelium in host defence against influenza virus infection. <i>Biomedical Journal</i> , 2018, 41, 218-233.	1.4	89
22	Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. <i>British Journal of Cancer</i> , 2018, 119, 1044-1051.	2.9	36
23	Contribution of innate immune cells to pathogenesis of severe influenza virus infection. <i>Clinical Science</i> , 2017, 131, 269-283.	1.8	31
24	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. <i>JCI Insight</i> , 2017, 2, e91868.	2.3	59
25	CTAS: a CT score to quantify disease activity in pulmonary sarcoidosis. <i>Thorax</i> , 2016, 71, 1161-1163.	2.7	26
26	MAIT cells are activated during human viral infections. <i>Nature Communications</i> , 2016, 7, 11653.	5.8	428
27	Abnormalities in iNKT cells are associated with impaired ability of monocytes to produce IL-10 and suppress T cell proliferation in sarcoidosis. <i>European Journal of Immunology</i> , 2014, 44, 2165-2174.	1.6	15
28	Lumps, bumps and diagnostic stumps. <i>British Journal of General Practice</i> , 2013, 63, 663-664.	0.7	0
29	Pivotal Advance: Invariant NKT cells reduce accumulation of inflammatory monocytes in the lungs and decrease immune-pathology during severe influenza A virus infection. <i>Journal of Leukocyte Biology</i> , 2011, 91, 357-368.	1.5	84
30	Alternative Spliced CD1D Transcripts in Human Bronchial Epithelial Cells. <i>PLoS ONE</i> , 2011, 6, e22726.	1.1	10
31	Reduction of Natural Killer but Not Effector CD8 T Lymphocytes in Three Consecutive Cases of Severe/Lethal H1N1/09 Influenza A Virus Infection. <i>PLoS ONE</i> , 2010, 5, e10675.	1.1	62
32	Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. <i>European Journal of Immunology</i> , 2008, 38, 1913-1922.	1.6	90
33	Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. <i>Lancet</i> , The, 2005, 365, 1062-1072.	6.3	82
34	CD4 ⁺ CD8 ⁺ Subset of CD1d-Restricted NKT Cells Controls T Cell Expansion. <i>Journal of Immunology</i> , 2004, 172, 7350-7358.	0.4	54
35	Reduced Interleukin-18 Levels in BAL Specimens From Patients With Asthma Compared to Patients With Sarcoidosis and Healthy Control Subjects. <i>Chest</i> , 2002, 121, 1421-1426.	0.4	44